Board of directors

The strategic committee of Op2lysis is composed of 6 members with complementary skills and experience. All are experts in their field. The committee is in charge of endorsing the corporate strategy. It is also in charge of following the implementation of the corporate project. The strength of this strategic committee relies in the complementarity of members’ experience, as well as in a strong commitment to Op2lysis.

Parcq Jérôme
Co-founder, General Manager

Co-founder of Op2lysis, Jérôme has extensive experience in neurovascular research and stroke.

With a training in Agronomy Engineering and a PhD in Neurosciences, Jérôme completed his scientific background with a training in entrepreneurship at HEC, Paris (Challenge + program).

Over the past ten years, Jérôme has worked in the Inserm Unit (U1237), led by Professor Denis Vivien in Caen, to develop innovative therapeutic solutions to destroy blood clots. He is the co-inventor of Opt-PA, the formulated O2L-001 molecule.

Jérôme is in charge of the company’s operational and research activities.

Gaudin Christophe
Co-founder, President

Doctor specialist and co-founder of the company, Christophe has been in charge of cardiovascular and thrombosis development at Sanofi for the past 20 years.

With a MD degree, he has successfully developed and registered internationally many cardiovascular drugs, including antithrombotic products now widely used in coronary artery diseases, such as myocardial infarction.

Christophe is in charge of the management of the company, and foresees development activities.

Müller Jean-Claude
With more than 20 years of experience in business development, Jean-Claude has worked for many years at Sanofi-Aventis. He was Senior Vice President in charge of Foresight and Strategic R&D Initiatives, which gave him the opportunity to establish long-term strategic corporate development scenarios. From 2005 to 2009, Jean-Claude was the founder and president of the Paris Region’s “Pôle de Compétitivité Medicen Région Paris”, the biomedical science cluster of the Paris Region.
Jean-Claude is a member of the strategic committee of Op2lysis , and was the first investor in love money when the company was created in April 2016.
Sempere Thierry
Président de la WICAP Op2Lysis

Thierry Sempere is the President of WICAP Op2lysis, the holding company representing the shareholders who invested in the first Op2lysis fundraising following a crowdfunding campaign with Wiseed.

Thierry’s professional career in the pharmaceutical industry, including high-level international operational experience, is a real contribution for the company.

Cassagne Patrick
Managing director of Cassagne et Associes, founded in 2004, Patrick Cassagne has been accompanying biotechnology companies for more than 10 years in the search for funds from investors, including Business Angels.
As part of the Op2lysis strategic committee, Patrick represents the Business Angels who have invested since the first Op2lysis fundraising and facilitates the continuation of their support.
Monteyne Philipe
With a, a specialty in neurology, and a Ph.D. in viral immunology, both at UCL (Univ. Cathol. de Louvain), Philippe is Advisor for Op2lysis.
Over the past 20 years, he has held leadership positions with major pharmaceutical companies such as Smithkline Beecham, GSK Biologicals (as a Leader in Global Vaccine Development) and GSK Rare Diseases (Head of Development and Head of Medical Services), and SANOFI (Vice President R&D France).